BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 15994922)

  • 1. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor.
    Weihrauch MR; Manzke O; Beyer M; Haverkamp H; Diehl V; Bohlen H; Wolf J; Schultze JL
    Cancer Res; 2005 Jul; 65(13):5516-9. PubMed ID: 15994922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A role for TARC/CCL17, a CC chemokine, in systemic lupus erythematosus.
    Okamoto H; Koizumi K; Yamanaka H; Saito T; Kamatani N
    J Rheumatol; 2003 Nov; 30(11):2369-73. PubMed ID: 14677179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum measurement of thymus and activation-regulated chemokine/CCL17 in children with atopic dermatitis: elevated normal levels in infancy and age-specific analysis in atopic dermatitis.
    Fujisawa T; Nagao M; Hiraguchi Y; Katsumata H; Nishimori H; Iguchi K; Kato Y; Higashiura M; Ogawauchi I; Tamaki K
    Pediatr Allergy Immunol; 2009 Nov; 20(7):633-41. PubMed ID: 19236603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The biological environment of Hodgkin's lymphoma and the role of the chemokine CCL17/TARC.
    Hnátková M; Mociková H; Trnený M; Zivný J
    Prague Med Rep; 2009; 110(1):35-41. PubMed ID: 19591376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell- attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis.
    Hijnen D; De Bruin-Weller M; Oosting B; Lebre C; De Jong E; Bruijnzeel-Koomen C; Knol E
    J Allergy Clin Immunol; 2004 Feb; 113(2):334-40. PubMed ID: 14767451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of the Th1 promoter IL-12 and the Th2 chemokine TARC are elevated in erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis and correlate with soluble Fas ligand expression. An immunoenzymatic study from the Italian Group of Immunopathology.
    Quaglino P; Caproni M; Antiga E; Del Bianco E; Osella-Abate S; Savoia P; Frezzolini A; Schena D; Marzano A; Volpi W; De Simone C; Parodi A; Fabbri P; Bernengo MG;
    Dermatology; 2007; 214(4):296-304. PubMed ID: 17460400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.
    Kurzrock R; Redman J; Cabanillas F; Jones D; Rothberg J; Talpaz M
    Cancer Res; 1993 May; 53(9):2118-22. PubMed ID: 8481913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Both Th1 and Th2 chemokines are elevated in sera of patients with autoimmune blistering diseases.
    Echigo T; Hasegawa M; Shimada Y; Inaoki M; Takehara K; Sato S
    Arch Dermatol Res; 2006 Jun; 298(1):38-45. PubMed ID: 16583210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased serum thymus and activation-regulated chemokine and cutaneous T cell-attracting chemokine levels in children with atopic dermatitis.
    Song TW; Sohn MH; Kim ES; Kim KW; Kim KE
    Clin Exp Allergy; 2006 Mar; 36(3):346-51. PubMed ID: 16499646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymus and activation regulated chemokines in children with atopic dermatitis: Kyushu University Ishigaki Atopic Dermatitis Study (KIDS).
    Furusyo N; Takeoka H; Toyoda K; Murata M; Maeda S; Ohnishi H; Fukiwake N; Uchi H; Furue M; Hayashi J
    Eur J Dermatol; 2007; 17(5):397-404. PubMed ID: 17673383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum thymus and activation-regulated chemokine level monitoring may predict disease relapse detected by PET scan after reduced-intensity allogeneic stem cell transplantation in patients with Hodgkin lymphoma.
    Farina L; Rezzonico F; Spina F; Dodero A; Mazzocchi A; Crippa F; Alessi A; Dalto S; Viviani S; Corradini P
    Biol Blood Marrow Transplant; 2014 Dec; 20(12):1982-8. PubMed ID: 25240818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Importance of determination of serum beta-2-microglobulin levels in patients with Hodgkin's lymphoma].
    Raida L; Papajík T; Hlusí A; Faber E; Urbanová R; Heczko M; Jancíková M; Zapletalová J; Komenda S; Indrák K
    Vnitr Lek; 2002 Feb; 48(2):91-5. PubMed ID: 11949228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma.
    Bien E; Balcerska A
    Scand J Immunol; 2009 Nov; 70(5):490-500. PubMed ID: 19874554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22.
    Niens M; Visser L; Nolte IM; van der Steege G; Diepstra A; Cordano P; Jarrett RF; Te Meerman GJ; Poppema S; van den Berg A
    Br J Haematol; 2008 Mar; 140(5):527-36. PubMed ID: 18275430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum thymus and activation-regulated chemokine, macrophage-derived chemokine and eotaxin as markers of severity of atopic dermatitis.
    Jahnz-Rozyk K; Targowski T; Paluchowska E; Owczarek W; Kucharczyk A
    Allergy; 2005 May; 60(5):685-8. PubMed ID: 15813816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
    Albitar M; Vose JM; Johnson MM; Do KA; Day A; Jilani I; Kantarjian H; Keating M; O'Brien SM; Verstovsek S; Armitage JO; Giles FJ
    Leuk Res; 2007 Feb; 31(2):139-45. PubMed ID: 16545870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis.
    Fujii H; Shimada Y; Hasegawa M; Takehara K; Sato S
    J Dermatol Sci; 2004 Jun; 35(1):43-51. PubMed ID: 15194146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High serum levels of B-lymphocyte stimulator are associated with clinical-pathological features and outcome in classical Hodgkin lymphoma.
    Tecchio C; Nadali G; Scapini P; Bonetto C; Visco C; Tamassia N; Vassilakopoulos TP; Pangalis GA; Calzetti F; Nardelli B; Roschke V; Gottardi M; Zampieri F; Gherlinzoni F; Facchetti F; Pizzolo G; Cassatella MA
    Br J Haematol; 2007 Jun; 137(6):553-9. PubMed ID: 17539776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte.
    Casasnovas RO; Mounier N; Brice P; Divine M; Morschhauser F; Gabarre J; Blay JY; Voillat L; Lederlin P; Stamatoullas A; Bienvenu J; Guiguet M; Intrator L; Grandjean M; Brière J; Ferme C; Salles G;
    J Clin Oncol; 2007 May; 25(13):1732-40. PubMed ID: 17389336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiogenic molecules in Hodgkin's disease: results from sequential serum analysis.
    Passam FH; Alexandrakis MG; Moschandrea J; Sfiridaki A; Roussou PA; Siafakas NM
    Int J Immunopathol Pharmacol; 2006; 19(1):161-70. PubMed ID: 16569354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.